Document Detail

Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
MedLine Citation:
PMID:  21813788     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO). METHODS: This was a chart review and telephone follow-up study of 99 patients with NMO spectrum of disorders (NMOSD) treated with azathioprine (1994-2009). NMOSD were NMO (2006 diagnostic criteria) or partial NMO forms (NMO-immunoglobulin G seropositive). Wilcoxon signed rank test was used to compare pretreatment and postinitiation of azathioprine (posttreatment) annualized relapse rates (ARR), Expanded Disability Status Scale (EDSS) score, and visual acuity outcome. Linear regression was used to assess the effects of various factors on ARR change and disability. RESULTS: The median duration of NMOSD symptoms prior to initiation of azathioprine was 2 years (range 1-27); 79 patients were women. Eighty-six patients had NMO and 13 limited NMO versions, including transverse myelitis in 8 and optic neuritis in 5. Median posttreatment follow-up was 22 months. Thirty-eight patients discontinued drug (side effects, 22; no efficacy, 13; lymphoma, 3). Among 70 patients with >12 months follow-up, 48 received ≥2.0 mg/kg/day (ARR: pretreatment, 2.20; posttreatment, 0.52); 22 received <2.0 mg/kg/day (ARR: pretreatment, 2.09; posttreatment, 0.82); 52 received concomitant prednisone (ARR: pretreatment, 2.20; posttreatment, 0.89) and 18 did not (ARR: pretreatment, 1.54; posttreatment, 0.23); p < 0.0001 for each comparison. EDSS was stable or improved despite ongoing attacks in 22 patients (31%). Twenty-six patients tolerated azathioprine and were relapse-free (37%, median follow-up 24 months; range 12-151). Mean corpuscular volume increase influenced ARR change (p = 0.049). CONCLUSIONS: Azathioprine is generally effective and well-tolerated. Early initiation, adequate dosing, and hematologic parameter monitoring may optimize efficacy. Classification of evidence: This study provides Class IV evidence that azathioprine is effective for reducing relapse rates and improving EDSS and visual acuity scores in patients with NMO spectrum of disorders.
C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon
Related Documents :
21686768 - Acute methaemoglobinaemia after massive nitrobenzene ingestion.
21733918 - Tachyphylaxis during treatment of exudative age-related macular degeneration with ranib...
21797808 - Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to ot...
10574168 - Do physical therapy and occupational therapy reduce the impairment percentage in reflex...
19593638 - Effects of diode laser therapy on the acellular dermal matrix.
3967438 - Total knee arthroplasty.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-3
Journal Detail:
Title:  Neurology     Volume:  -     ISSN:  1526-632X     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-8-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Departments of Neurology (C.C., M.M., C.F.L., B.G.W., S.J.P., A.M.), Biostatistics (J.M., P.T.), and Laboratory Medicine and Pathology (S.J.P., A.M.), Mayo Clinic College of Medicine, Rochester, MN.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Longitudinal changes of structural connectivity in traumatic axonal injury.
Next Document:  Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more eff...